CO5130028A1 - Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr - Google Patents
Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfrInfo
- Publication number
- CO5130028A1 CO5130028A1 CO99052263A CO99052263A CO5130028A1 CO 5130028 A1 CO5130028 A1 CO 5130028A1 CO 99052263 A CO99052263 A CO 99052263A CO 99052263 A CO99052263 A CO 99052263A CO 5130028 A1 CO5130028 A1 CO 5130028A1
- Authority
- CO
- Colombia
- Prior art keywords
- cup
- proliferation
- cells
- egfr
- hypersecretion
- Prior art date
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title abstract 3
- 230000003042 antagnostic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 210000003097 mucus Anatomy 0.000 abstract 4
- 230000035755 proliferation Effects 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 238000010874 in vitro model Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002345 respiratory system Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Otolaryngology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9702398P | 1998-08-18 | 1998-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5130028A1 true CO5130028A1 (es) | 2002-02-27 |
Family
ID=22260380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99052263A CO5130028A1 (es) | 1998-08-18 | 1999-08-18 | Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr |
Country Status (35)
| Country | Link |
|---|---|
| US (6) | US6270747B1 (https=) |
| EP (2) | EP1119349B1 (https=) |
| JP (2) | JP2002539072A (https=) |
| KR (1) | KR100609646B1 (https=) |
| CN (1) | CN1184961C (https=) |
| AR (1) | AR020220A1 (https=) |
| AT (1) | ATE399541T1 (https=) |
| AU (1) | AU760766B2 (https=) |
| BR (1) | BR9912672A (https=) |
| CA (1) | CA2337422C (https=) |
| CO (1) | CO5130028A1 (https=) |
| CY (1) | CY1110370T1 (https=) |
| CZ (1) | CZ2001584A3 (https=) |
| DE (1) | DE69939022D1 (https=) |
| DK (1) | DK1119349T3 (https=) |
| EA (1) | EA004316B1 (https=) |
| EE (1) | EE200100097A (https=) |
| ES (1) | ES2310047T3 (https=) |
| HR (1) | HRP20010119B1 (https=) |
| HU (1) | HUP0103894A3 (https=) |
| ID (1) | ID27345A (https=) |
| IL (2) | IL140855A0 (https=) |
| MY (1) | MY126490A (https=) |
| NO (1) | NO327000B1 (https=) |
| NZ (1) | NZ509271A (https=) |
| PH (2) | PH12010000216A1 (https=) |
| PL (1) | PL200940B1 (https=) |
| PT (1) | PT1119349E (https=) |
| RS (1) | RS50273B (https=) |
| SI (1) | SI1119349T1 (https=) |
| SK (1) | SK287805B6 (https=) |
| TR (1) | TR200100560T2 (https=) |
| TW (1) | TWI250019B (https=) |
| UA (1) | UA73722C2 (https=) |
| WO (1) | WO2000010588A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US6270747B1 (en) | 1998-08-18 | 2001-08-07 | The University Of California | In vitro and in vivo assay for agents which treat mucus hypersecretion |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20030236300A1 (en) * | 1999-10-27 | 2003-12-25 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| WO2002094318A1 (en) * | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
| US6818446B2 (en) | 2001-11-21 | 2004-11-16 | The Regents Of The University Of California | Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| US7105576B2 (en) * | 2002-04-24 | 2006-09-12 | Research Development Foundation | Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents |
| WO2004000229A2 (en) * | 2002-06-24 | 2003-12-31 | Research Development Foundation | Treatment of human multiple myeloma by curcumin |
| EP1587482A4 (en) * | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | INFLAMMATORY COMPOSITIONS AND ITS USES |
| US7195899B1 (en) * | 2003-03-14 | 2007-03-27 | Florida State University Research Foundation, Inc. | Cell-based biosensor for harmful airborne agents |
| AU2004320907A1 (en) | 2003-08-26 | 2006-04-13 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
| WO2005020958A2 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Aerosol delivery of curcumin |
| US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| US8846079B1 (en) | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| US8134010B2 (en) * | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
| US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| EP1753734A1 (en) * | 2004-05-05 | 2007-02-21 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US7968575B2 (en) * | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
| US6998028B1 (en) * | 2004-09-24 | 2006-02-14 | Superpower, Inc. | Methods for forming superconducting conductors |
| US7504381B2 (en) * | 2004-09-27 | 2009-03-17 | Technion Research & Development Foundation Ltd. | Antimicrobial agents |
| US7915223B2 (en) * | 2004-09-27 | 2011-03-29 | Technion Research & Development Foundation Ltd. | Antimicrobial agents |
| JP4690158B2 (ja) * | 2004-09-28 | 2011-06-01 | スギ生物科学研究所株式会社 | 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法 |
| US20080072338A1 (en) * | 2004-09-28 | 2008-03-20 | Fuji Biomedix Co., Ltd | Animal for Drug Efficacy Evaluation, Method for Developing Chronic Obstructive Pulmonary Disease in Animal for Drug Efficacy Evaluation, and Method for Evaluating Drug Efficacy Using the Animal |
| EP1933624A4 (en) * | 2005-10-11 | 2009-09-16 | Univ Washington | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY TRACT HYPERSECRETION |
| EP1921070A1 (de) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| AU2008212999A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
| US20080293740A1 (en) * | 2007-04-03 | 2008-11-27 | Parion Sciences, Inc. | Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders |
| EP2152289A1 (en) * | 2007-04-30 | 2010-02-17 | Technion Research & Development Foundation Ltd. | Novel antimicrobial agents |
| US20100173832A1 (en) * | 2007-04-30 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Anticancerous polymeric agents |
| US8497369B2 (en) | 2008-02-07 | 2013-07-30 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production |
| EP2313397B1 (de) * | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US8112365B2 (en) * | 2008-12-19 | 2012-02-07 | Foster Scott C | System and method for online employment recruiting and evaluation |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| US8597695B1 (en) | 2010-11-13 | 2013-12-03 | Sirbal Ltd. | Herbal combinations for treatment of a skin condition |
| US8541382B2 (en) | 2010-11-13 | 2013-09-24 | Sirbal Ltd. | Cardiac glycoside analogs in combination with emodin for cancer therapy |
| US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
| EP3513787A1 (en) * | 2011-01-10 | 2019-07-24 | Invion, Inc | Use of beta-adrenergic inverse agonists for smoking cessation |
| US10036009B2 (en) | 2012-08-03 | 2018-07-31 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| EP3782604A1 (en) | 2013-07-31 | 2021-02-24 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| WO2015082950A1 (en) | 2013-12-02 | 2015-06-11 | Sirbal Ltd. | Herbal combinations for treatment of a skin condition |
| EP3328498B1 (en) | 2015-07-29 | 2021-05-05 | Sirbal Ltd. | Medical kit comprising herbal combinations for treating psoriasis |
| HK1258650A1 (zh) | 2015-09-14 | 2019-11-15 | Vgsk Technologies, Inc. | 皮下、舌下和口服治疗用空间稳定载体、用於治疗哺乳动物的组合物和方法 |
| US20240118267A1 (en) * | 2021-03-03 | 2024-04-11 | Hannah Viola | Cell culture growth apparatus and method of underside attachment to a surface using cell seeding |
| WO2022235907A1 (en) | 2021-05-05 | 2022-11-10 | Vgsk Technologies, Inc. | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2932481A (en) * | 1954-06-15 | 1960-04-12 | Breer | Bipod camera support |
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| FR2502627A1 (fr) * | 1981-02-02 | 1982-10-01 | Refarmed Sa | Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent |
| IT1173549B (it) * | 1984-04-02 | 1987-06-24 | Corvi Camillo Spa | Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4904786A (en) * | 1986-01-27 | 1990-02-27 | American Home Products Corporation | Quinoline compounds as antiallergic and antiinflammatory agents |
| US5089516A (en) * | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| KR900701771A (ko) * | 1988-09-28 | 1990-12-04 | 로버트 에이 아미테이지 | 리폭시게나아제 효소를 억제하는 1, 4-디히드로티오나프토퀴논 및 헤테로시클릭 협동 작용물 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8904009D0 (en) | 1989-02-22 | 1989-04-05 | Celltech Ltd | Vector |
| US5362755A (en) * | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| CA2082160C (en) * | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| US5116616A (en) * | 1991-04-29 | 1992-05-26 | Bio-Technology General Corp. | Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation |
| DE4117078A1 (de) | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
| DE69230613T2 (de) | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| DE4310051A1 (de) | 1992-04-11 | 1993-10-14 | Byk Gulden Lomberg Chem Fab | Weitere Verwendung substituierter Pyridazine |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| JP2801085B2 (ja) * | 1992-09-11 | 1998-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ヒト細胞を植えた気道上の異種移植片を有する非ヒト動物 |
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| WO1995006764A2 (en) | 1993-09-03 | 1995-03-09 | Vpi Holdings Ltd. | Oligonucleotides with rna cleavage activity |
| JP3436311B2 (ja) * | 1993-09-13 | 2003-08-11 | メルク フロスト カナダ アンド カンパニー | 粘液分泌性上皮細胞の化生変化を測定する方法 |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| EP0746614A1 (en) | 1994-02-23 | 1996-12-11 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US20030114379A1 (en) * | 1994-03-08 | 2003-06-19 | Human Genome Sciences, Inc. | Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| JPH11507329A (ja) | 1995-04-27 | 1999-06-29 | ゼネカ リミテッド | キナゾリン誘導体 |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| EA001595B1 (ru) * | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| US5990097A (en) * | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New teatment |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
| CA2322311C (en) * | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
| US6270747B1 (en) | 1998-08-18 | 2001-08-07 | The University Of California | In vitro and in vivo assay for agents which treat mucus hypersecretion |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CA2361174C (en) | 1999-02-27 | 2009-10-27 | Boehringer Ingelheim Pharma Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| CA2387351C (en) * | 1999-10-19 | 2009-09-08 | Merck & Co., Inc. | Indole derivatives as tyrosine kinase inhibitors |
| WO2001077104A1 (de) | 2000-04-08 | 2001-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US6627634B2 (en) * | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
-
1999
- 1999-08-17 US US09/375,597 patent/US6270747B1/en not_active Expired - Lifetime
- 1999-08-17 JP JP2000565908A patent/JP2002539072A/ja active Pending
- 1999-08-17 RS YU13201A patent/RS50273B/sr unknown
- 1999-08-17 CA CA2337422A patent/CA2337422C/en not_active Expired - Fee Related
- 1999-08-17 EA EA200100136A patent/EA004316B1/ru not_active IP Right Cessation
- 1999-08-17 SK SK216-2001A patent/SK287805B6/sk not_active IP Right Cessation
- 1999-08-17 SI SI9931016T patent/SI1119349T1/sl unknown
- 1999-08-17 EP EP99943729A patent/EP1119349B1/en not_active Expired - Lifetime
- 1999-08-17 PL PL351765A patent/PL200940B1/pl not_active IP Right Cessation
- 1999-08-17 KR KR1020017002114A patent/KR100609646B1/ko not_active Expired - Fee Related
- 1999-08-17 HU HU0103894A patent/HUP0103894A3/hu unknown
- 1999-08-17 TR TR2001/00560T patent/TR200100560T2/xx unknown
- 1999-08-17 NZ NZ509271A patent/NZ509271A/en not_active IP Right Cessation
- 1999-08-17 DK DK99943729T patent/DK1119349T3/da active
- 1999-08-17 HR HR20010119A patent/HRP20010119B1/xx not_active IP Right Cessation
- 1999-08-17 IL IL14085599A patent/IL140855A0/xx active IP Right Grant
- 1999-08-17 AU AU56766/99A patent/AU760766B2/en not_active Ceased
- 1999-08-17 ES ES99943729T patent/ES2310047T3/es not_active Expired - Lifetime
- 1999-08-17 DE DE69939022T patent/DE69939022D1/de not_active Expired - Lifetime
- 1999-08-17 CZ CZ2001584A patent/CZ2001584A3/cs unknown
- 1999-08-17 CN CNB998095745A patent/CN1184961C/zh not_active Expired - Fee Related
- 1999-08-17 WO PCT/US1999/018696 patent/WO2000010588A2/en not_active Ceased
- 1999-08-17 AT AT99943729T patent/ATE399541T1/de active
- 1999-08-17 BR BR9912672-9A patent/BR9912672A/pt not_active IP Right Cessation
- 1999-08-17 EE EEP200100097A patent/EE200100097A/xx unknown
- 1999-08-17 UA UA2001021134A patent/UA73722C2/uk unknown
- 1999-08-17 PT PT99943729T patent/PT1119349E/pt unknown
- 1999-08-17 EP EP08009498A patent/EP1970058A1/en not_active Withdrawn
- 1999-08-17 TW TW088114306A patent/TWI250019B/zh not_active IP Right Cessation
- 1999-08-17 ID IDW20010322A patent/ID27345A/id unknown
- 1999-08-18 CO CO99052263A patent/CO5130028A1/es unknown
- 1999-08-18 MY MYPI99003537A patent/MY126490A/en unknown
- 1999-08-19 AR ARP990104149A patent/AR020220A1/es not_active Application Discontinuation
-
2001
- 2001-01-10 IL IL140855A patent/IL140855A/en not_active IP Right Cessation
- 2001-02-14 NO NO20010749A patent/NO327000B1/no not_active IP Right Cessation
- 2001-02-26 US US09/794,232 patent/US6566324B2/en not_active Expired - Lifetime
- 2001-05-24 US US09/865,239 patent/US6551989B2/en not_active Expired - Lifetime
-
2003
- 2003-02-07 US US10/359,932 patent/US7358222B2/en not_active Expired - Fee Related
- 2003-02-07 US US10/359,982 patent/US8048844B1/en not_active Expired - Fee Related
-
2008
- 2008-02-27 US US12/038,718 patent/US8071074B2/en not_active Expired - Fee Related
- 2008-09-26 CY CY20081101062T patent/CY1110370T1/el unknown
-
2009
- 2009-05-22 JP JP2009123658A patent/JP2009221212A/ja active Pending
-
2010
- 2010-07-21 PH PH12010000216A patent/PH12010000216A1/en unknown
- 2010-07-21 PH PH12010000215A patent/PH12010000215A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5130028A1 (es) | Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr | |
| ATE378058T1 (de) | Cannabis extrakten pharmazeutische zusammensetzung | |
| NO20073337L (no) | Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1 | |
| BR0311867A (pt) | Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| UA73004C2 (uk) | Біциклічні гетероцикли та лікувальний засіб на їх основі | |
| DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| SE9704833D0 (sv) | New formulation | |
| CR7152A (es) | Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias. | |
| UY27757A1 (es) | Medicamento que contiene betamiméticos y un nuevo anticolinérgico. | |
| EA200801698A1 (ru) | Лекарственные композиции для применения в вагине | |
| CR8850A (es) | Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales | |
| DK1128835T3 (da) | Cyanocobalamin (vitamin 12)-behandling ved allergisk sygdom | |
| AR033024A1 (es) | Conjugados de pregabalina-lactosa | |
| WO2022258972A1 (en) | Nitroxoline for use in the treatment of cutaneous neurofibroma | |
| ATE444754T1 (de) | Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür | |
| ES2145517T3 (es) | Nuevos derivados monofuncionalizados de edta, dtpa y ttha y su utilizacion en el diagnostico y en la terapia medicinales. | |
| Ansarin et al. | Xanthoma disseminatum with tumor‐like lesion on face | |
| DE502005001659D1 (de) | Schleimdrogenbasierte Lutschtablette gegen entzündliche Erkrankungen des Mund- und Rachenraums | |
| BRPI0508053A (pt) | método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto | |
| Feshchenko et al. | The procedure of adaptation of international quality of life questionnaire MOS SF-36 in Ukraine: the experience of administration in asthma patients | |
| Ferlito et al. | Developmental lesions of the head and neck | |
| PL1871340T3 (pl) | Łagodzący podrażnienie środek przeciwkaszlowy, zawierający wyciągi z mchu islandzkiego i ślazu oraz związki cynkowe |